Supplementary Table 1: the Physical Performance Test
Supplementary Table 1:The Physical Performance Test
Scoring1. / Write a sentence.
(Whales live in the blue ocean.) / ≤ 10 sec = 4
10.5-15 sec = 3
15.5 – 20 sec = 2
>20 sec = 1
unable = 0
2. / Simulated eating / ≤ 10 sec = 4
10.5-15 sec = 3
15.5 – 20 sec = 2
>20 sec = 1
unable = 0
3. / Lift a book and put it on a shelf
Bed height 59 cm
Shelf height 118 cm
All sitting with feet on floor / ≤ 2 sec = 4
2.5- 4 sec = 3
4.5 – 6 sec = 2
> 6 sec = 1
unable = 0
4. / Put on and remove a jacket
- Standing
- Use of bathrobe; button down shirt; hospital gown.
10.5-15 sec = 3
15.5 – 20 sec = 2
>20 sec = 1
unable = 0
5. / Pick up a penny from floor. / ≤ 2 sec = 4
2.5- 4 sec = 3
4.5 – 6 sec = 2
> 6 sec = 1
unable = 0
6. / Turn 360 degrees / Discontinuous steps = 0
Continuous steps = 2
Unsteady
(grabs, staggers) = 0
Steady = 2
7. / 50-foot walk test.
Starting sitting for instructions. / ≤ 15 sec = 4
15.5- 20 sec = 3
20.5 – 25 sec = 2
>25 sec = 1
unable = 0
Supplementary Table 2: Characteristics of study cohort
Parameter / Median (Range)Age (years) / 74 (60 – 93)
WHO performance status / 1 (0 – 4)
Karnofsky performance status / 90 (10 – 100)
ADL / 100 (15 – 100)
IADL / 7 (1 – 8)
TUG (seconds) / 11.21 (4 – 97.12)
MMSE / 27 (14 – 30)
F-SozU / 4.5 (1.91 – 5)
GDS 30 / 7 (0 – 27)
CIRS-Gt / 6 (0 – 17)
Polypharmacy / 5 (0 – 14)
PPT / 17.5 (0 – 28)
VES-13 / 2 (0 – 9)
Number of impairments / 3 (0 – 8)
Abbreviations, see Table 1
Supplementary Table 3: Discriminative power of PPT, VES-13 and G8 based on data from the literature
n / Patients included / % frail on screening / % frail on ger ass / Sens / Spec / PPV / NPVPPT
Augschoell et al (2014) / 77 / various types of cancer / 79% / 70% / 82% / 75% / 89% / 63%
G8
Baitar et al (2011), Eu J Cancer / 135 / various types of cancer / 75% / 44% / 92% / 39% / 55% / 85%
Baitar et al (2013), J GeriatrOncol / 170 / various types of cancer / 76% / 64% / 92% / 52% / 78% / 78%
Kenis et al (2009), Crit Rev OncolHematol / 140 / various types of cancer / 76% / 79% / 80% / 40% / 83% / 35%
Kenis et al (2011), J Geriatric Oncol / 843 / various types of cancer / 74% / 73% / 87% / 61% / 86% / 63%
Kenis et al (2014), J ClinOncol / 937 / various types of cancer / 74% / 74% / 87% / 59% / 86% / 61%
Pottel et al (2011-12), J Geriatric Oncol, J ClinOncol / 51 / head and neck cancer / 67% / 69% / 86% / 75% / 88% / 71%
Soubeyran et al (2008), J ClinOncol / 364 / various types of cancer / 82% / 94% / 85% / 65% / 97% / 22%
Soubeyran et al (2011), J Geriatric Oncol / 1425 / unclear / 68% / 80% / 77% / 64% / 90% / 41%
Hamaker et al (2013), Ann Hem / 108 / hematological malignancies / 70% / 61% / 69% / 79% / 89% / 50%
VES-13
Augschoell et al (2014) / 77 / various types of cancer / 42% / 70% / 56% / 91% / 94% / 45%
Kellen et al (2010), Crit Rev OncolHematol / 113 / various types of cancer / 49% / 68% / 61% / 78% / 85% / 48%
Luciani et al (2010), J ClinOncol / 419 / various types of cancer / 54% / 28% / 87% / 62% / 45% / 93%
Mohile et al (2007), Cancer / 50 / prostate cancer receiving hormone treatment / 50% / 60% / 73% / 86% / 89% / 67%
Molina-Garrido et al (2008-11), Crit Rev OncolHematol / 41 / breast cancer / 29% / 56% / 55% / 100% / 100% / 66%
Molina-Garrido et al (2011), EuGeriatr Med / 58 / unclear / 35% / 88% / 39% / 10% / 100% / 18%
Monfardini et al (2010), J ClinOncol / 150 / breast cancer / 46% / 44% / 68% / 71% / 65% / 74%
Owusu et al (2010), J GeriatrOncol / 117 / various types of cancer / 56% / 43% / 88% / 69% / 68% / 88%
Pottel et al (2011-12) J GeriatrOncol, J ClinOncol / 51 / head and neck cancer / 39% / 69% / 57% / 100% / 100% / 52%
Soubeyran et al (2011), J Geriatric Oncol / 1425 / unclear / 60% / 80% / 69% / 74% / 92% / 37%
Supplementary Figure 1 a: Discriminative power of VES-13 ≥3 for impairments in geriatric assessment as assessed by ROC
Supplementary Figure 1 b: Discriminative power of PPT ≤20 for impairments in geriatric assessment as assessed by ROC
Supplementary Figure 1 c: Discriminative power of PPT ≤19 for impairments in geriatric assessment as assessed by ROC